8-Amino-3,8-diazabicyclo <3.2.1> oktan | 38074-10-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 8-Amino-3,8-diazabicyclo <3.2.1> oktan
• 英文别名: 3,8-diaza-bicyclo[3.2.1]oct-8-ylamine；3,8-Diazabicyclo[3.2.1]octan-8-amine
• CAS: 38074-10-1
• 化学式: C₆H₁₃N₃
• mdl: MFCD19221329
• 分子量: 127.189
• InChiKey: UYQFLZIFNAJGHN-UHFFFAOYSA-N

物化性质

• 沸点：
  210.2±33.0 °C(Predicted)
• 密度：
  1.081±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS<br/>[FR] CARBOXAMIDES UTILISÉES EN TANT QU'INHIBITEURS DE PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2019032863A1

  公开（公告）日：2019-02-14

  The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

  本公开涉及调节剂，如抑制剂，至少选择自USP28和USP25中的一条途径的药物组合物包括这些抑制剂，以及使用这些抑制剂的方法。这些调节剂，如抑制剂，至少选择自USP28和USP25中的一条途径，可用于治疗癌症等疾病。
• Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
  申请人：Xie Wenge

  公开号：US20050250808A1

  公开（公告）日：2005-11-10

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明一般涉及尼古丁型乙酰胆碱受体（nACh受体）的配体领域，nACh受体的激活，以及与缺陷或功能异常的尼古丁型乙酰胆碱受体相关的疾病状况的治疗，尤其是大脑的治疗。此外，本发明涉及新型化合物（吲唑和苯并噻唑），其作为α7 nACh受体亚型的配体，制备此类化合物的方法，含有此类化合物的组合物，以及使用这些方法。
• [EN] BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE ERBB POUR LE TRAITEMENT DU CANCER
  申请人：CAPELLA THERAPEUTICS INC

  公开号：WO2015143161A1

  公开（公告）日：2015-09-24

  Provided herein are benzimidazole derivatives, for example, of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

  本文提供苯并咪唑衍生物，例如，Formula (I)的化合物及其药物组合物。本文还提供了它们用于治疗、预防或改善增殖性疾病一个或多个症状的方法。
• INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF
  申请人：Xie Wenge

  公开号：US20090118232A1

  公开（公告）日：2009-05-07

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明涉及乙酰胆碱受体配体(nACh受体)、nACh受体的激活以及与缺陷或失灵的乙酰胆碱受体相关的疾病状态的治疗，特别是大脑的治疗领域。此外，本发明涉及新型化合物(吲唑和苯并噻唑)，这些化合物作为α7 nACh受体亚型的配体，制备这些化合物的方法，含有这些化合物的组合物以及使用这些组合物的方法。
• HETEROCYCLIC SUBSTITUTED PYRIMIDINE COMPOUND
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：EP2735567A1

  公开（公告）日：2014-05-28

  The present invention pertains to the field of medical technology, and particularly relates to a heterocyclic substituted pyrimidine compound represented by General Formula (I) and its pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description, the present invention also relates to a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound and the pharmaceutical composition in preparation of a medicine for enhancing a cGMP signal transduction function or a medicine for treating or preventing sexual dysfunction and diseases with lower urinary tract symptoms.

  本发明涉及医药技术领域，尤其涉及一种由通式(I)代表的杂环取代的嘧啶化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5如描述中所定义，本发明还涉及该化合物的制备方法、本发明还涉及该化合物的制备方法、含有该化合物的药物组合物，以及该化合物和药物组合物在制备增强 cGMP 信号转导功能的药物或治疗或预防性功能障碍和下尿路症状疾病的药物中的用途。